Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Cameron Liu"'
Autor:
Sohan Dua, Cameron Liu, Charles Bradley, Khalil G. Saikali, Robert Leong, Dylan Steer, Lynda A. Szczech, Edouard R Martin, Marializa V. Bernardo, Kin-Hung Peony Yu, Chaim Charytan, Meraf Eyassu, Roberto Manllo-Karim, Moustafa A. Moustafa, Gopal Saha
Publikováno v:
Kidney International Reports
Introduction Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylas
Autor:
Charles Bradley, Lona Poole, Robert Leong, Anatole Besarab, Liubov Eremeeva, Lynda A. Szczech, Meraf Eyassu, Thomas B. Neff, Kin-Hung Peony Yu, Evgeny Shutov, Cameron Liu, Robert Provenzano, Gopal Saha, Svitlana Korneyeva
Publikováno v:
Nephrology Dialysis Transplantation. 36:1717-1730
Background We evaluated the efficacy and safety of roxadustat versus epoetin alfa for the treatment of chronic kidney disease-related anemia in patients new to dialysis. Methods HIMALAYAS was a Phase 3, open-label, epoetin alfa-controlled trial. Elig
Autor:
Xueqing Yu, Cameron Liu, Qiang He, Jiaqi Qian, Nan Chen, Hongli Lin, Anatole Besarab, Frank H. Valone, Xuemei Li, Li Zuo, Chuanming Hao, Kin-Hung Peony Yu, Lynda A. Szczech, Jianghua Chen, Ping Fu, Dalvin Ni, Gengru Jiang, Changlin Mei, Stefan Hemmerich, Xinzhou Zhang, Thomas B. Neff
Publikováno v:
Nephrology Dialysis Transplantation
Background FG-4592 (roxadustat) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (HIF-PHI) promoting coordinated erythropoiesis through the transcription factor HIF. Two Phase 2 studies were conducted in China to explore the saf
Autor:
Li Zuo, Laimin Luo, Cai-Li Wang, Bi-Cheng Liu, Zhihong Liu, Thomas B. Neff, Xinling Liang, Zhengrong Liu, Chuanming Hao, Li Hao, Hongli Lin, Robert Leong, Jianqin Wang, Cameron Liu, Nan Chen, Changying Xing, Guang-Yan Cai, Xuemei Li, Ming-Hui Zhao, Kin-Hung Peony Yu, Lynda A. Szczech, Chunrong Wang, Gengru Jiang
Publikováno v:
The New England journal of medicine. 381(11)
Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Additional data are needed regarding the effectiveness and safety of roxadustat as compared with standard therap
Autor:
Zhengrong Liu, Bi-Cheng Liu, Nan Chen, Kin-Hung Peony Yu, Chunrong Wang, Xinling Liang, Yunhua Liao, Laimin Luo, Thomas B. Neff, Xiaomei Peng, Hongli Lin, Li Zuo, Cameron Liu, Ye Tao, Aiping Yin, Changying Xing, Li Hao, Robert Leong, Jianghua Chen, Chuanming Hao, Lynda A. Szczech
Publikováno v:
The New England journal of medicine. 381(11)
Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In phase 2 studies involving patients with chronic kidney disease, roxadustat increased level
Autor:
Tim, Heise, Susanne, Bott, Corinna, Tusek, Jens-Armin, Stephan, Tom, Kawabata, Deborah, Finco-Kent, Cameron, Liu, Alan, Krasner
Publikováno v:
Diabetes care. 28(9)
To assess the impact of the development of high- or low-affinity insulin antibodies (IABs) on postprandial glucose tolerance, duration of insulin action, and clinical safety in patients with type 1 diabetes receiving inhaled insulin (Exubera).This st
Autor:
Cameron Liu, Susanne Bott, Alan Krasner, Tom Kawabata, Deborah Finco-Kent, Tim Heise, Corinna Tusek, Jens-Armin Stephan
Publikováno v:
Diabetes Care. 29:477-478
OBJECTIVE—To assess the impact of the development of high- or low-affinity insulin antibodies (IABs) on postprandial glucose tolerance, duration of insulin action, and clinical safety in patients with type 1 diabetes receiving inhaled insulin (Exub